{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:32:29Z","timestamp":1788838349040,"version":"build-2803163510"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005629","name":"Stiftung Tier\u00e4rztliche Hochschule Hannover","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005629","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.nbd.2025.106917","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T12:22:34Z","timestamp":1744806154000},"page":"106917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Sinbaglustat ameliorates disease pathology in a murine model of GM1 gangliosidosis without affecting CNS ganglioside levels"],"prefix":"10.1016","volume":"210","author":[{"given":"Rouven","family":"Wannemacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Jubran-Rudolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Zdora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Leitzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Rohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Sippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Paschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Blattmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Baumg\u00e4rtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Gerhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel Alexander","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2\u20133","key":"10.1016\/j.nbd.2025.106917_bb0005","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10545-006-0272-5","article-title":"Substrate reduction therapy of glycosphingolipid storage disorders","volume":"29","author":"Aerts","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.nbd.2025.106917_bb0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajmg.1320310108","article-title":"Inherited lysosomal storage disease associated with deficiencies of beta-galactosidase and alpha-neuraminidase in sheep","volume":"31","author":"Ahern-Rindell","year":"1988","journal-title":"Am. J. Med. Genet."},{"issue":"3","key":"10.1016\/j.nbd.2025.106917_bb0015","first-page":"675","article-title":"Canine GM1-gangliosidosis. A clinical, morphologic, histochemical, and biochemical comparison of two different models","volume":"140","author":"Alroy","year":"1992","journal-title":"Am. J. Pathol."},{"issue":"152\u2013157","key":"10.1016\/j.nbd.2025.106917_bb0020","article-title":"The clinical and molecular Spectrum of GM1 Gangliosidosis","volume":"215","author":"Arash-Kaps","year":"2019","journal-title":"J. Pediatr."},{"issue":"6","key":"10.1016\/j.nbd.2025.106917_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021758","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease","volume":"6","author":"Ashe","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.nbd.2025.106917_bb0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol. Med."},{"issue":"10","key":"10.1016\/j.nbd.2025.106917_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013468","article-title":"AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival","volume":"5","author":"Baek","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.nbd.2025.106917_bb0040","first-page":"649","article-title":"Animal model: feline GM1 gangliosidosis","volume":"74","author":"Baker","year":"1974","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.nbd.2025.106917_bb0045","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.nbd.2025.106917_bb0050","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-011-9368-7","article-title":"Gastrointestinal disturbances and their management in miglustat-treated patients","volume":"34","author":"Belmatoug","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.nbd.2025.106917_bb0055","series-title":"Biochemistry. Ninth edition. edn","author":"Berg","year":"2019"},{"issue":"2","key":"10.1016\/j.nbd.2025.106917_bb0060","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2307\/1591870","article-title":"Gangliosidosis in emus (Dromaius novaehollandiae)","volume":"39","author":"Bermudez","year":"1995","journal-title":"Avian Dis."},{"issue":"2","key":"10.1016\/j.nbd.2025.106917_bb0065","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1074\/jbc.M610544200","article-title":"Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2","volume":"282","author":"Boot","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2025.106917_bb0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.nbd.2017.06.003","article-title":"N-butyldeoxynojirimycin delays motor deficits, cerebellar microgliosis, and Purkinje cell loss in a mouse model of mucolipidosis type IV","volume":"105","author":"Boudewyn","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.nbd.2025.106917_bb0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ymgme.2008.04.012","article-title":"GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects","volume":"94","author":"Brunetti-Pierri","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.nbd.2025.106917_bb0080","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10545-012-9561-3","article-title":"Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes","volume":"36","author":"Burke","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.nbd.2025.106917_bb0085","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Ital. J. Pediatr."},{"issue":"2","key":"10.1016\/j.nbd.2025.106917_bb0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ymgme.2015.12.002","article-title":"Enzyme replacement for GM1-gangliosidosis: uptake, lysosomal activation, and cellular disease correction using a novel beta-galactosidase:RTB lectin fusion","volume":"117","author":"Condori","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.nbd.2025.106917_bb0095","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/sj.cdd.4401834","article-title":"Gangliosides as apoptotic signals in ER stress response","volume":"13","author":"d\u2019Azzo","year":"2006","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.nbd.2025.106917_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.11.002","article-title":"Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study","volume":"138","author":"Deegan","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.nbd.2025.106917_bb0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0034-5288(18)33872-4","article-title":"Beta-galactosidase deficiency in GM1 gangliosidosis of Friesian calves","volume":"15","author":"Donnelly","year":"1973","journal-title":"Res. Vet. Sci."},{"issue":"7","key":"10.1016\/j.nbd.2025.106917_bb0110","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/sj.embor.embor873","article-title":"X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease","volume":"4","author":"Dvir","year":"2003","journal-title":"EMBO Rep."},{"issue":"4","key":"10.1016\/j.nbd.2025.106917_bb0115","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/jcm9041004","article-title":"Axonopathy and reduction of membrane resistance: key features in a new murine model of human GM1-Gangliosidosis","volume":"9","author":"Eikelberg","year":"2020","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.nbd.2025.106917_bb0120","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ymgme.2008.02.005","article-title":"Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis","volume":"94","author":"Elliot-Smith","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.nbd.2025.106917_bb0125","author":"EMA approval Zavesca"},{"key":"10.1016\/j.nbd.2025.106917_bb0130","series-title":"U.S. Food and Drug Administration","author":"FDA approval Brineura","year":"2017"},{"key":"10.1016\/j.nbd.2025.106917_bb0135","author":"FDA approval Zavesca"},{"issue":"2","key":"10.1016\/j.nbd.2025.106917_bb0140","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/TCRM.S6865","article-title":"Review of miglustat for clinical management in Gaucher disease type 1","volume":"4","author":"Ficicioglu","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"issue":"10","key":"10.1016\/j.nbd.2025.106917_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1371","article-title":"Substrate reduction therapy with Miglustat in pediatric patients with GM1 type 2 gangliosidosis delays neurological involvement: a multicenter experience","volume":"8","author":"Fischetto","year":"2020","journal-title":"Mol. Genet. Genomic Med."},{"key":"10.1016\/j.nbd.2025.106917_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1392683","article-title":"Therapeutic developments for neurodegenerative GM1 gangliosidosis","volume":"18","author":"Foster","year":"2024","journal-title":"Front. Neurosci."},{"issue":"12","key":"10.1016\/j.nbd.2025.106917_bb0155","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.bbamem.2006.08.004","article-title":"Intracellular trafficking of sphingolipids: relationship to biosynthesis","volume":"1758","author":"Futerman","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.nbd.2025.106917_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075091","article-title":"Increased neurofilament light chain blood levels in neurodegenerative neurological diseases","volume":"8","author":"Gaiottino","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.nbd.2025.106917_bb0165","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/cts.12911","article-title":"Assessment of target engagement in a first-in-human trial with Sinbaglustat, an Iminosugar to treat lysosomal storage disorders","volume":"14","author":"Gehin","year":"2021","journal-title":"Clin. Transl. Sci."},{"issue":"2","key":"10.1016\/j.nbd.2025.106917_bb0170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/ml100192b","article-title":"Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars","volume":"2","author":"Ghisaidoobe","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.nbd.2025.106917_bb0175","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ymthe.2017.01.009","article-title":"Novel biomarkers of human GM1 Gangliosidosis reflect the clinical efficacy of gene therapy in a feline model","volume":"25","author":"Gray-Edwards","year":"2017","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.nbd.2025.106917_bb0180","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an Iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement","volume":"103","author":"Guerard","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.nbd.2025.106917_bb0185","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/hmg\/6.2.205","article-title":"Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase","volume":"6","author":"Hahn","year":"1997","journal-title":"Hum. Mol. Genet."},{"issue":"Suppl. 1","key":"10.1016\/j.nbd.2025.106917_bb0190","first-page":"S28","article-title":"Gene therapy for GM1 gangliosidosis: challenges of translational medicine","volume":"3","author":"Hayward","year":"2015","journal-title":"Ann. Transl. Med."},{"issue":"1\u20132","key":"10.1016\/j.nbd.2025.106917_bb0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jneuroim.2012.04.010","article-title":"Interleukin-10 expression during the acute phase is a putative prerequisite for delayed viral elimination in a murine model for multiple sclerosis","volume":"249","author":"Herder","year":"2012","journal-title":"J. Neuroimmunol."},{"issue":"9","key":"10.1016\/j.nbd.2025.106917_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138107","article-title":"Visualization of active Glucocerebrosidase in rodent brain with high spatial resolution following in situ labeling with fluorescent activity based probes","volume":"10","author":"Herrera Moro Chao","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.nbd.2025.106917_bb0205","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0962-8924(98)01249-5","article-title":"Glucosylceramide synthase and glycosphingolipid synthesis","volume":"8","author":"Ichikawa","year":"1998","journal-title":"Trends Cell Biol."},{"issue":"2","key":"10.1016\/j.nbd.2025.106917_bb0210","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ymgme.2017.04.011","article-title":"Infantile gangliosidoses: mapping a timeline of clinical changes","volume":"121","author":"Jarnes Utz","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"11","key":"10.1016\/j.nbd.2025.106917_bb0215","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.96.11.6388","article-title":"Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin","volume":"96","author":"Jeyakumar","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.nbd.2025.106917_bb0220","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1471-4159.2004.02381.x","article-title":"N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis","volume":"89","author":"Kasperzyk","year":"2004","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.nbd.2025.106917_bb0225","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1194\/jlr.M400411-JLR200","article-title":"Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice","volume":"46","author":"Kasperzyk","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.nbd.2025.106917_bb0230","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.cellbio.21.122303.120013","article-title":"Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids","volume":"21","author":"Kolter","year":"2005","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.nbd.2025.106917_bb0235","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1534\/genetics.105.042580","article-title":"A duplication in the canine beta-galactosidase gene GLB1 causes exon skipping and GM1-gangliosidosis in Alaskan huskies","volume":"170","author":"Kreutzer","year":"2005","journal-title":"Genetics"},{"issue":"4","key":"10.1016\/j.nbd.2025.106917_bb0240","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1750-3639.2011.00541.x","article-title":"Axonopathy is associated with complex axonal transport defects in a model of multiple sclerosis","volume":"22","author":"Kreutzer","year":"2012","journal-title":"Brain Pathol."},{"issue":"1","key":"10.1016\/j.nbd.2025.106917_bb0245","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1358\/dot.2006.42.1.937457","article-title":"Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders","volume":"42","author":"Lachmann","year":"2006","journal-title":"Drugs Today (Barc.)"},{"issue":"1","key":"10.1016\/j.nbd.2025.106917_bb0250","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1038\/s41598-019-40964-1","article-title":"Virus-triggered spinal cord demyelination is followed by a peripheral neuropathy resembling features of Guillain-Barre syndrome","volume":"9","author":"Leitzen","year":"2019","journal-title":"Sci. Rep."},{"issue":"26","key":"10.1016\/j.nbd.2025.106917_bb0255","doi-asserted-by":"crossref","first-page":"23594","DOI":"10.1074\/jbc.M300212200","article-title":"Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms","volume":"278","author":"Lloyd-Evans","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.nbd.2025.106917_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135889","article-title":"Reducing GBA2 activity ameliorates neuropathology in Niemann-pick type C mice","volume":"10","author":"Marques","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.nbd.2025.106917_bb0265","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of Neuronopathic Gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.nbd.2025.106917_bb0270","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ymthe.2019.05.018","article-title":"Substrate reduction therapy for Sandhoff disease through inhibition of glucosylceramide synthase activity","volume":"27","author":"Marshall","year":"2019","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.nbd.2025.106917_bb0275","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0387-7604(96)00077-0","article-title":"Neurological manifestations of knockout mice with beta-galactosidase deficiency","volume":"19","author":"Matsuda","year":"1997","journal-title":"Brain Dev."},{"issue":"4","key":"10.1016\/j.nbd.2025.106917_bb0280","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.conb.2011.05.025","article-title":"The multiple roles of Purkinje cells in sensori-motor calibration: to predict, teach and command","volume":"21","author":"Medina","year":"2011","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.nbd.2025.106917_bb0285","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.conb.2021.11.004","article-title":"GBA mutations, glucosylceramide and Parkinson\u2019s disease","volume":"72","author":"Milenkovic","year":"2022","journal-title":"Curr. Opin. Neurobiol."},{"issue":"13","key":"10.1016\/j.nbd.2025.106917_bb0290","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1073\/pnas.1400768111","article-title":"Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease","volume":"111","author":"Mistry","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.nbd.2025.106917_bb0295","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/mds.20193","article-title":"Clinical features of adult GM1 gangliosidosis: report of three Indian patients and review of 40 cases","volume":"19","author":"Muthane","year":"2004","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.nbd.2025.106917_bb0300","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2014.02.002","article-title":"GM1-gangliosidosis in American black bears: clinical, pathological, biochemical and molecular genetic characterization","volume":"111","author":"Muthupalani","year":"2014","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.nbd.2025.106917_bb0315","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ymgme.2012.01.020","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-pick C mice","volume":"105","author":"Nietupski","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"3831","key":"10.1016\/j.nbd.2025.106917_bb0320","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1126\/science.160.3831.1002","article-title":"Generalized Gangliosidosis - Beta-Galactosidase Deficiency","volume":"160","author":"Okada","year":"1968","journal-title":"Science"},{"issue":"41","key":"10.1016\/j.nbd.2025.106917_bb0325","doi-asserted-by":"crossref","first-page":"26522","DOI":"10.1074\/jbc.273.41.26522","article-title":"Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase","volume":"273","author":"Overkleeft","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.nbd.2025.106917_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108113","article-title":"First-in-human single-dose study of nizubaglustat, a dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramidase: safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending and multiple doses in healthy adults","volume":"141","author":"Paquet Luzy","year":"2024","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.nbd.2025.106917_bb0335","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13023-018-0844-0","article-title":"Miglustat in Niemann-pick disease type C patients: a review","volume":"13","author":"Pineda","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"issue":"457","key":"10.1016\/j.nbd.2025.106917_bb0340","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","article-title":"Substrate reduction therapy","volume":"97","author":"Platt","year":"2008","journal-title":"Acta Paediatr."},{"issue":"5311","key":"10.1016\/j.nbd.2025.106917_bb0345","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.276.5311.428","article-title":"Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin","volume":"276","author":"Platt","year":"1997","journal-title":"Science"},{"issue":"1433","key":"10.1016\/j.nbd.2025.106917_bb0350","first-page":"947","article-title":"Substrate reduction therapy in mouse models of the glycosphingolipidoses","volume":"358","author":"Platt","year":"2003","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.nbd.2025.106917_bb0355","article-title":"Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS\/MS","volume":"55","author":"Polo","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"issue":"2","key":"10.1016\/j.nbd.2025.106917_bb0360","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ymgme.2018.11.002","article-title":"Comprehensive behavioral and biochemical outcomes of novel murine models of GM1-gangliosidosis and Morquio syndrome type B","volume":"126","author":"Przybilla","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.nbd.2025.106917_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005063","article-title":"Accumulation of glucosylceramide in the absence of the beta-glucosidase GBA2 alters cytoskeletal dynamics","volume":"11","author":"Raju","year":"2015","journal-title":"PLoS Genet."},{"issue":"4263","key":"10.1016\/j.nbd.2025.106917_bb0370","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1126\/science.824730","article-title":"Neuronal-visceral GM1 gangliosidosis in a dog with beta-galactosidase deficiency","volume":"194","author":"Read","year":"1976","journal-title":"Science"},{"issue":"36","key":"10.1016\/j.nbd.2025.106917_bb0375","doi-asserted-by":"crossref","first-page":"26052","DOI":"10.1074\/jbc.M113.463562","article-title":"beta-glucosidase 2 (GBA2) activity and imino sugar pharmacology","volume":"288","author":"Ridley","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"25","key":"10.1016\/j.nbd.2025.106917_bb0380","doi-asserted-by":"crossref","first-page":"10195","DOI":"10.1523\/JNEUROSCI.0822-13.2013","article-title":"Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis","volume":"33","author":"Sandhoff","year":"2013","journal-title":"J. Neurosci."},{"issue":"20","key":"10.1016\/j.nbd.2025.106917_bb0385","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular Cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.nbd.2025.106917_bb0390","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s40265-015-0468-9","article-title":"Eliglustat: a review in Gaucher disease type 1","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.nbd.2025.106917_bb0395","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ymgme.2013.03.015","article-title":"Glucosylceramide modulates endolysosomal pH in Gaucher disease","volume":"109","author":"Sillence","year":"2013","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.nbd.2025.106917_bb0400","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF00309632","article-title":"A new form of ovine GM1-gangliosidosis","volume":"89","author":"Skelly","year":"1995","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2025.106917_bb0405","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.omtm.2021.08.003","article-title":"Real-time MR tracking of AAV gene therapy with betagal-responsive MR probe in a murine model of GM1-gangliosidosis","volume":"23","author":"Taghian","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"5","key":"10.1016\/j.nbd.2025.106917_bb0410","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.molcel.2004.08.029","article-title":"GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis","volume":"15","author":"Tessitore","year":"2004","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.nbd.2025.106917_bb0415","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00401-004-0848-9","article-title":"The leukoencephalopathy of infantile GM1 gangliosidosis: oligodendrocytic loss and axonal dysfunction","volume":"107","author":"van der Voorn","year":"2004","journal-title":"Acta Neuropathol."},{"issue":"13","key":"10.1016\/j.nbd.2025.106917_bb0420","first-page":"3654","article-title":"Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase","volume":"63","author":"Weiss","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.nbd.2025.106917_bb0425","article-title":"Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients","volume":"30","author":"Welford","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.nbd.2025.106917_bb0430","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nbd.2014.03.001","article-title":"Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-pick disease type C1 mice","volume":"67","author":"Williams","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"2\u20133","key":"10.1016\/j.nbd.2025.106917_bb0435","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s10545-006-0239-6","article-title":"Limitations of enzyme replacement therapy: current and future","volume":"29","author":"Wraith","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.nbd.2025.106917_bb0440","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ymgme.2009.12.006","article-title":"Miglustat in adult and juvenile patients with Niemann-pick disease type C: long-term data from a clinical trial","volume":"99","author":"Wraith","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.nbd.2025.106917_bb0445","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/ehf2.13025","article-title":"Cardiovascular prognosis: a new role for ceramides and other cardiometabolites","volume":"7","author":"Wu","year":"2020","journal-title":"ESC Heart Fail."},{"issue":"11","key":"10.1016\/j.nbd.2025.106917_bb0450","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1172\/JCI29224","article-title":"Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility","volume":"116","author":"Yildiz","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"16","key":"10.1016\/j.nbd.2025.106917_bb0455","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0960-9822(01)00396-7","article-title":"Critical role for glycosphingolipids in Niemann-Pick disease type C","volume":"11","author":"Zervas","year":"2001","journal-title":"Curr. Biol."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996125001330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996125001330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T21:46:46Z","timestamp":1770846406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996125001330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":89,"alternative-id":["S0969996125001330"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2025.106917","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sinbaglustat ameliorates disease pathology in a murine model of GM1 gangliosidosis without affecting CNS ganglioside levels","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2025.106917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106917"}}